GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (OSTO:BIOG B) » Definitions » Altman Z-Score

BioGaia AB (OSTO:BIOG B) Altman Z-Score : 25.53 (As of Dec. 15, 2024)


View and export this data going back to 1998. Start your Free Trial

What is BioGaia AB Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 25.53 is strong.

BioGaia AB has a Altman Z-Score of 25.53, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for BioGaia AB's Altman Z-Score or its related term are showing as below:

OSTO:BIOG B' s Altman Z-Score Range Over the Past 10 Years
Min: 16.81   Med: 31.08   Max: 47.98
Current: 25.53

During the past 13 years, BioGaia AB's highest Altman Z-Score was 47.98. The lowest was 16.81. And the median was 31.08.


BioGaia AB Altman Z-Score Historical Data

The historical data trend for BioGaia AB's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGaia AB Altman Z-Score Chart

BioGaia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.87 41.14 27.18 23.51 22.83

BioGaia AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.29 22.83 26.29 25.41 26.19

Competitive Comparison of BioGaia AB's Altman Z-Score

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB's Altman Z-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Altman Z-Score falls into.



BioGaia AB Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

BioGaia AB's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.6846+1.4*0+3.3*0.2284+0.6*38.7452+1.0*0.7117
=25.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2024:
Total Assets was kr1,905 Mil.
Total Current Assets was kr1,497 Mil.
Total Current Liabilities was kr192 Mil.
Retained Earnings was kr0 Mil.
Pre-Tax Income was 46.981 + 142.752 + 153.599 + 88.191 = kr432 Mil.
Interest Expense was -2.29 + -1.481 + -1.545 + 1.785 = kr-4 Mil.
Revenue was 303.971 + 384.122 + 369.796 + 297.773 = kr1,356 Mil.
Market Cap (Today) was kr11,047 Mil.
Total Liabilities was kr285 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1496.501 - 192.362)/1904.921
=0.6846

X2=Retained Earnings/Total Assets
=0/1904.921
=0

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(431.523 - -3.531)/1904.921
=0.2284

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=11046.924/285.117
=38.7452

X5=Revenue/Total Assets
=1355.662/1904.921
=0.7117

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

BioGaia AB has a Altman Z-Score of 25.53 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


BioGaia AB  (OSTO:BIOG B) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


BioGaia AB Altman Z-Score Related Terms

Thank you for viewing the detailed overview of BioGaia AB's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


BioGaia AB Business Description

Traded in Other Exchanges
Address
Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.

BioGaia AB Headlines

No Headlines